ALK and non-small cell lung carcinoma: Based on these results, alectinib has been recently approved by the FDA as a first-line treatment in ALK-positive NSCLC, leading one to wonder whether there will still be room for crizotinib in the treatment algorithm of patients with ALK rearrangements.